ArticlePharmacogenomics and personalized medicine2026
Low Frequency of HLA-B*15:02 in Northwest China: Implications for Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Screening Strategies.
Article in Pharmacogenomics and personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: HLA-B*15:02 is an important genetic marker for predicting carbamazepine (CBZ)-induced Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) in Asian populations. This descriptive pooled analysis aimed to characterize HLA-B*15:02 distribution in Northwest China and inform regional screening strategies. Methods: We genotyped HLA-B*15:02 via next-generation sequencing (NGS) in 98 healthy volunteers from Ningxia, and combined these data with 11 previously published studies (total N=3400) from Northwest China. Weighted means, medians, and interquartile ranges (IQR) were calculated by region and ethnicity, with Pearson's chi‑square tests for group comparisons (significance threshold: Results: The overall HLA-B*15:02 frequency was 1.81% (range: 0.00%-3.30%; IQR: 0.24-1.97%). Regional weighted frequencies were 2.12% (Qinghai), 1.98% (Shaanxi), 1.02% (Ningxia), and 0.38% (Xinjiang); ethnic frequencies ranged from 0% (Kazakh) to 2.28% (Hui). No significant regional (χ Conclusion: The overall frequency of HLA-B*15:02 in Northwest China is 1.81%, substantially lower than in South China, suggesting a lower expected yield of routine screening in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.